Evidence map›Paper›PMID 30698715›Full record

SynthesisInflammatory bowel diseases2019

The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.

Edward L Barnes, Bharati Kochar, Hilary R Jessup, Hans H Herfarth

3 registry-linked trialsOpen access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 57 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 5 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06312683 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2024 to 2027Enrolled16ConditionsPouchitisArmsRifaximin 550 MG Oral Tablet [XIFAXAN]
NCT06864403 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2025 to 2027Enrolled25ConditionsPouchitis, Pouches, Ileoanal, Pouch, IlealArmsMirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
NCT07756359 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2026 to 2027Enrolled20ConditionsPouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryArmsTirzepatide, Loperamide, Diphenoxylate/Atropine
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 5 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Approach to Therapy for Chronic Pouchitis.Annual review of medicine · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Edward L BarnesDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Bharati KocharDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Hilary R JessupSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Hans H HerfarthDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
University of North Carolina at Chapel Hill · US

Funding

PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
NIDDK NIH HHS P30 DK034987
6 · The paper itself

Abstract

backgroundA subset of patients who undergo total proctocolectomy with ileal pouch-anal anastomosis (IPAA) creation for ulcerative colitis (UC) will later develop Crohn's disease (CD) of the pouch, which has been associated with significant morbidity. We aimed to analyze the incidence of CD of the pouch and to review the existing diagnostic criteria utilized.

methodsA systematic search performed through March 1, 2018, identified 12 studies that reported the incidence of CD of the pouch after IPAA for UC or indeterminate colitis (IC). We compiled all diagnostic criteria utilized in these studies and then performed a meta-analysis using random effects modeling to estimate the overall incidence of CD of the pouch in this population.

resultsAmong 4843 patients with an IPAA for UC or IC, 10.3% of patients were ultimately diagnosed with CD of the pouch (95% confidence interval [CI], 6.1%-15.4%). The most commonly reported diagnostic criteria were (1) presence of fistula/fistulae, (2) stricture involving the pouch or prepouch ileum, and (3) presence of prepouch ileitis. In a secondary analysis, excluding those studies that included patients with a preoperative diagnosis of IC, the incidence of CD of the pouch was 12.4% (95% CI, 9.0%-16.1%).

conclusionsThe estimated incidence of 10.3% will assist gastroenterologists and surgeons in preoperative counseling regarding the potential to develop CD of the pouch. There is an unmet need for common diagnostic criteria for a more standardized approach to the diagnosis of CD of the pouch.

Indexed as

Colitis, UlcerativeCrohn DiseaseHumansIncidencePouchitisProctocolectomy, RestorativePrognosisUnited StatesCD of the pouchfistulapouch strictureprepouch ileitis

Identifiers

PMID30698715
PMCPMC6703435
OpenAlexW2911291912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.